Screener
Spyre Therapeutics, Inc. SYRE Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development (1) | 60,411 | 41,623 |
| General and administrative (2) | 15,230 | 11,944 |
| Gain on sale of in-process research and development asset | (30,000) | — |
| Total operating expenses | 45,641 | 53,567 |
| Loss from operations | (45,641) | (53,567) |
| Other (expense) income: | ||
| Interest income | 6,995 | 6,493 |
| Other (expense) income, net | (30,359) | 2,286 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s total operating expenses?
- Spyre Therapeutics, Inc. (SYRE) reported total operating expenses of $45.64M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total operating expenses changed year-over-year?
- Spyre Therapeutics, Inc.'s total operating expenses decreased by 14.8% year-over-year, from $53.57M to $45.64M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total operating expenses?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s total operating expenses has grown at a 25.5% compound annual growth rate (CAGR), from $84.39M to $209.56M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Spyre Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude